Autor: Erwin G. Van Meir
ISBN-13: 9781603275521
Veröffentl: 01.09.2009
Einband: Buch
Seiten: 1284
Gewicht: 2064 g
Format: 245x165x66 mm
Sprache: Englisch

CNS Cancer

Cancer Drug Discovery and Development
Models, Markers, Prognostic Factors, Targets, and Therapeutic Approaches

Sie erhalten für diesen Artikel

Bücher Thöne Punkte: 706

Sofort lieferbar | * inkl. MwSt ggf. zzgl. Versandkosten
353,09 € 353,05 € *
This volume covers three areas of research in brain tumors: animal models for brain tumors; prognostic factors and biomarkers; therapeutic targets and targeting approaches to brain tumors. It has 160 illustrations, 64 in color, and two 16-page color inserts.
Chapter 1: PDGF-Based Malignant Glioma Model in Rats and Mice.- Chapter 2: Modeling Brain Tumors Using Avian Retroviral Gene Transfer.- Chapter 3: Using Neurofibromatosis Type 1 Mouse Models to Understand Human Pediatric Low-Grade Gliomas.- Chapter 4: Transgenic Mouse Models of CNS Tumors: Using Genetically Engineered Murine Models to Study the Role p21-Ras in Glioblastoma Multiforme.- Chapter 5: Pten-Deficient Mouse Models for High-Grade Astrocytomas.- Chapter 6: The NF1/p53 Knockout Transgenic Model for Malignant Glioma.- Chapter 7: Conditional Models for Brain Tumors in Transgenic Mice.- Chapter 8: Human Brain Tumor Cell and Tumor Tissue Transplantation Models.- Chapter 9: Transformation of Human Brain Cells in Culture as Models for Brain Tumors.- Chapter 10: History of Important Carcinogen-Induced Brain Tumor Cell Lines.- Chapter 11: Neuro-Oncogenesis Induced by Nitroso-Compounds in Rodents and Strain-Specific Genetic Modifiers of Predisposition.- Chapter 12: The Murine GL261 Glioma Experimental Model to Assess Novel Brain Tumor Treatments.- Chapter 13: Spontaneous Occurrence of Brain Tumors in Animals: Opportunities as Preclinical Model Systems.- Chapter 14: P53 Alterations in Brain Tumors.- Chapter 15: The PTEN/PI3 Kinase Pathway in Human Glioma.- Chapter 16: Value of 1p/19q and Other LOH Markers for Brain Tumor Diagnosis, Prognosis and Therapy.- Chapter 17: Discovery of Genetic Markers for Brain Tumors by Comparative Genomic Hybridization.- Chapter 18: Genomic Identification of Significant Targets in Brain Cancer.- Chapter 19: Oncogenic Pathway Markers.- Chapter 20: Aberrant EGFR Signaling in Glioma.- Chapter 21: Mechanisms of Brain Tumor Angiogenesis.- Chapter 22: Vaso-Occlusive Mechanisms that Intiate Hypoxia and Necrosis in Glioblastoma: The Role of Thrombosis and Tissue Factor.- Chapter 23: Expression Profiling of Glioblastoma Defines Distinct Subtypes.- Chapter 24: Proteomic Profiling of Human Brain Tumors.- Chapter 25: Discovery of Biomarkers in the Cerebrospinal Fluid of Brain Tumor Patients.- Chapter 26: Epigenetic Profiling of Gliomas.- Chapter 27: Micro RNAs in the Central Nervous System and Potential Roles of RNA Interference in Brain Tumors.- Chapter 28: Understanding Glioma Resistance to Temozolomide Therapy.- Chapter 29: Markers of Cancer Stem Cells for Brain Tumor Prognosis.- Chapter 30: Clinical Agents for the Targeting of Brain Tumor Vasculature.- Chapter 31: GBM Neovascularization: Impact of Bone Marrow-Derived Cells and Evasive Mechanisms of Antiangiogenic Therapy.- Chapter 32: Novel Phage and Viral Targeting Vehicles for Brain Tumor Therapy.- Chapter 33: Impact of the Blood Brain Barrier on Brain Tumor Imaging and Therapy.- Chapter 34: Targeting CXCR4 in Brain Tumors.- Chapter 35: Molecular Targeting of IL-13Ra2 and EphA2 Receptor in GBM.- Chapter 36: Brain Tumor Targets for Antibody-Mediated Immuno-Therapy.- Chapter 37: STAT3 Oncogenic Signaling in Brain Tumors.- Chapter 38: Inhibition of Ras Signaling in Brain Tumors.- Chapter 39: HGF/c-Met Signaling and Targeted Therapeutics in Brain Tumors.- Chapter 40: Combinatorial Therapeutic Strategy for Blocking Kinase Pathways in Brain Tumors.- Chapter 41: Targeting of TRAIL Apoptotic Pathways for Glioblastoma Therapies.- Chapter 42: The NF-kB Signaling Pathway in GBMs, Implications for Apoptotic and Inflammatory Responses and Exploitation for Therapy.- Chapter 43: Targeting Endoplasmic Reticulum Stress for Malignant Glioma Therapy.- Chapter 44: Targeting Adult and Pediatric Brain Cancer Stem Cells.- Chapter 45: The Use of Retinoids as Differentiation Agents Against Medulloblastoma.- Chapter 46: Herpes Simplex Virus 1 (HSV-1) for Glioblastoma Multiforme Therapy.- Chapter 47: The Development of Targeted Cancer Gene-Therapy Adenoviruses for High-Grade Glioma Treatment.- Chapter 48: Harnessing T-cell Immunity to Target Brain Tumors.- Chapter 49: Glioma Invasion: Mechanisms and Therapeutic Challenges.-
Cancers of the central nervous system are among the most lethal of human neoplasms. They are recalcitrant to even intensive multimodality therapies that include surgery, radiotherapy, and chemotherapy. Moreover, especially in children, the consequences of these therapies can itself be devastating and involve serious cognitive and developmental disorders. It is small wonder that such cancers have come under the intense scrutiny of each of the subspecialties of clinical care and investigation as well as attracting some of the best basic research scientists. Their joint efforts are gradually peeling away the mysteries surrounding the genesis and progression of these tumors and inroads are being steadily made into understanding why they resist therapies. This makes it an especially opportune time to assemble some of the best investigators in the field to review the ''state of the art'' in the various arenas that comprise the assault on CNS tumors. The breadth of this effort by the clinical and basic neuro-oncology community is quite simply amazing. To a large extent, it evolves from the knowledge of the human genome and its regulation that has been hard won over the past two decades.
Editiert von: Erwin G. Van Meir
Erwin G Van Meir is Professor of Neurosurgery and Hematology & Medical Oncology in the School of Medicine at Emory University. A native of Belgium, he obtained Bachelor's degrees in Biology and Education at the University of Fribourg, Switzerland. He pursued graduate studies in Molecular Virology at the University of Lausanne, Switzerland where he obtained his PhD in 1989. He then became interested in cancer and pursued postdoctoral work at the University Hospital in Lausanne and at the Ludwig Institute for Cancer Research in San Diego. In 1994 he became a Junior Faculty and Director of the Laboratory of Brain Tumor Biology and Genetics in the Neurosurgery Department at the University of Lausanne. In 1998 he joined Emory University in Atlanta, where he now serves as the Leader of the Winship Cancer Institute Molecular Pathways and Biomarkers scientific program and as the co-Director of the brain tumor working group.

Zu diesem Artikel ist noch keine Rezension vorhanden.
Helfen sie anderen Besuchern und verfassen Sie selbst eine Rezension.

Schreiben Sie Ihre Meinung
und verdienen Sie sich 10 Bonuspunkte

> neue Rezension schreiben


Autor: Erwin G. Van Meir
ISBN-13:: 9781603275521
ISBN: 1603275525
Erscheinungsjahr: 01.09.2009
Verlag: Springer-Verlag GmbH
Gewicht: 2064g
Seiten: 1284
Sprache: Englisch
Sonstiges: Buch, 245x165x66 mm, 96 schwarz-weiße und 64 farbige Abbildungen, 46 Tabellen